Company / PP&E (Net)
GYRE THERAPEUTICS, INC. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$23.6M
FY2025
5-year range
$970.0K / $23.9M
FY2021-FY2025
Trend
-1.2%
vs FY2024
Sector context
#74 of 193
Health Care
What the data says
At $24M, GYRE THERAPEUTICS, INC.'s pp&e (net) ranks #74 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $276,000 in FY2017 to $24M in FY2024.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +122.5%.
Remained stable around $24M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +10.0%
- 5-Year CAGR
- +122.5%
- 10-Year CAGR
- -
Sector benchmark
#74 of 193 in Health CareTop 38% of 193This company $23.6M Sector average $777.6M
▼
-97.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +122.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 1.2% year-over-year.
- Ranks #74 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.6M | -1.2% |
| FY2024 | $23.9M | +2.5% |
| FY2023 | $23.3M | +31.5% |
| FY2022 | $17.7M | +1725.7% |
| FY2021 | $970.0K | +124.0% |
| FY2020 | $433.0K | +42.4% |
| FY2019 | $304.0K | -21.2% |
| FY2018 | $386.0K | +39.9% |
| FY2017 | $276.0K | -37.8% |
| FY2016 | $444.0K | -36.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026